vs

Side-by-side financial comparison of ACV Auctions Inc. (ACVA) and BIOCRYST PHARMACEUTICALS INC (BCRX). Click either name above to swap in a different company.

ACV Auctions Inc. is the larger business by last-quarter revenue ($183.6M vs $156.4M, roughly 1.2× BIOCRYST PHARMACEUTICALS INC). On growth, ACV Auctions Inc. posted the faster year-over-year revenue change (15.1% vs 7.5%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs 12.3%).

ACV Auctions Inc. operates a leading digital wholesale vehicle auction platform serving automotive dealers across the U.S. and Canada. It offers end-to-end services including transparent vehicle inspections, secure payment processing, and logistics support, enabling efficient trading of used vehicles between registered wholesale buyers and sellers.

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

ACVA vs BCRX — Head-to-Head

Bigger by revenue
ACVA
ACVA
1.2× larger
ACVA
$183.6M
$156.4M
BCRX
Growing faster (revenue YoY)
ACVA
ACVA
+7.7% gap
ACVA
15.1%
7.5%
BCRX
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
19.6%
12.3%
ACVA

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ACVA
ACVA
BCRX
BCRX
Revenue
$183.6M
$156.4M
Net Profit
Gross Margin
Operating Margin
-9.7%
13.6%
Net Margin
Revenue YoY
15.1%
7.5%
Net Profit YoY
EPS (diluted)
$-0.12
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACVA
ACVA
BCRX
BCRX
Q1 26
$156.4M
Q4 25
$183.6M
$406.6M
Q3 25
$199.6M
$159.4M
Q2 25
$193.7M
$163.4M
Q1 25
$182.7M
$145.5M
Q4 24
$159.5M
$131.5M
Q3 24
$171.3M
$117.1M
Q2 24
$160.6M
$109.3M
Net Profit
ACVA
ACVA
BCRX
BCRX
Q1 26
Q4 25
$245.8M
Q3 25
$-24.5M
$12.9M
Q2 25
$-7.3M
$5.1M
Q1 25
$-14.8M
$32.0K
Q4 24
$-26.8M
Q3 24
$-16.0M
$-14.0M
Q2 24
$-17.1M
$-12.7M
Gross Margin
ACVA
ACVA
BCRX
BCRX
Q1 26
Q4 25
97.7%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Operating Margin
ACVA
ACVA
BCRX
BCRX
Q1 26
13.6%
Q4 25
-9.7%
64.0%
Q3 25
-11.9%
18.6%
Q2 25
-3.7%
18.2%
Q1 25
-7.9%
14.6%
Q4 24
-16.2%
-3.4%
Q3 24
-10.0%
6.6%
Q2 24
-11.6%
8.0%
Net Margin
ACVA
ACVA
BCRX
BCRX
Q1 26
Q4 25
60.5%
Q3 25
-12.3%
8.1%
Q2 25
-3.8%
3.1%
Q1 25
-8.1%
0.0%
Q4 24
-20.4%
Q3 24
-9.4%
-12.0%
Q2 24
-10.6%
-11.6%
EPS (diluted)
ACVA
ACVA
BCRX
BCRX
Q1 26
$0.00
Q4 25
$-0.12
$1.13
Q3 25
$-0.14
$0.06
Q2 25
$-0.04
$0.02
Q1 25
$-0.09
$0.00
Q4 24
$-0.15
$-0.13
Q3 24
$-0.10
$-0.07
Q2 24
$-0.10
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACVA
ACVA
BCRX
BCRX
Cash + ST InvestmentsLiquidity on hand
$271.5M
$259.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$429.7M
Total Assets
$1.1B
$465.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACVA
ACVA
BCRX
BCRX
Q1 26
$259.0M
Q4 25
$271.5M
$274.7M
Q3 25
$265.3M
$212.9M
Q2 25
$258.4M
$260.0M
Q1 25
$291.9M
$295.1M
Q4 24
$224.1M
$320.9M
Q3 24
$252.5M
$96.8M
Q2 24
$215.0M
$78.4M
Stockholders' Equity
ACVA
ACVA
BCRX
BCRX
Q1 26
Q4 25
$429.7M
$-119.2M
Q3 25
$434.4M
$-387.9M
Q2 25
$448.8M
$-421.6M
Q1 25
$439.6M
$-451.9M
Q4 24
$440.0M
$-475.9M
Q3 24
$456.2M
$-468.6M
Q2 24
$457.6M
$-475.6M
Total Assets
ACVA
ACVA
BCRX
BCRX
Q1 26
$465.1M
Q4 25
$1.1B
$514.2M
Q3 25
$1.2B
$446.4M
Q2 25
$1.1B
$457.2M
Q1 25
$1.2B
$480.0M
Q4 24
$984.1M
$490.4M
Q3 24
$1.0B
$491.3M
Q2 24
$1.0B
$472.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACVA
ACVA
BCRX
BCRX
Operating Cash FlowLast quarter
$-12.4M
Free Cash FlowOCF − Capex
$-14.7M
FCF MarginFCF / Revenue
-8.0%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$69.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACVA
ACVA
BCRX
BCRX
Q1 26
Q4 25
$-12.4M
$292.0M
Q3 25
$10.3M
$41.6M
Q2 25
$13.7M
$41.3M
Q1 25
$66.6M
$-27.5M
Q4 24
$-3.2M
$-5.2M
Q3 24
$21.1M
$8.2M
Q2 24
$4.5M
$-1.4M
Free Cash Flow
ACVA
ACVA
BCRX
BCRX
Q1 26
Q4 25
$-14.7M
$291.2M
Q3 25
$7.7M
$40.3M
Q2 25
$10.9M
$41.1M
Q1 25
$65.3M
$-27.7M
Q4 24
$-3.9M
$-5.9M
Q3 24
$20.2M
$8.2M
Q2 24
$2.7M
$-1.5M
FCF Margin
ACVA
ACVA
BCRX
BCRX
Q1 26
Q4 25
-8.0%
71.6%
Q3 25
3.8%
25.3%
Q2 25
5.6%
25.2%
Q1 25
35.7%
-19.0%
Q4 24
-2.5%
-4.5%
Q3 24
11.8%
7.0%
Q2 24
1.7%
-1.4%
Capex Intensity
ACVA
ACVA
BCRX
BCRX
Q1 26
Q4 25
1.2%
0.2%
Q3 25
1.3%
0.8%
Q2 25
1.5%
0.1%
Q1 25
0.7%
0.1%
Q4 24
0.4%
0.5%
Q3 24
0.6%
0.1%
Q2 24
1.1%
0.1%
Cash Conversion
ACVA
ACVA
BCRX
BCRX
Q1 26
Q4 25
1.19×
Q3 25
3.23×
Q2 25
8.12×
Q1 25
-859.91×
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACVA
ACVA

Auction Marketplace Revenue$77.6M42%
Other Marketplace Revenue$72.4M39%
Customer Assurance$24.1M13%
Data Services Revenue$9.4M5%

BCRX
BCRX

ORLADEYO$148.3M95%
Other revenues$5.0M3%
License revenue$3.0M2%

Related Comparisons